Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
31 hedge funds and large institutions have $69.4M invested in Bellerophon Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
19% more funds holding
Funds holding: 26 → 31 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
16% less capital invested
Capital invested by funds: $82.3M → $69.4M (-$12.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$509K |
| 2 |
TI
Telemetry Investments
New York
|
+$254K |
| 3 |
Renaissance Technologies
New York
|
+$224K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$148K |
| 5 |
JP Morgan Chase
New York
|
+$47.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$339K |
| 2 |
VF
Virtu Financial
New York
|
-$146K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$79K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$31.5K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$12.1K |
BLPH Hedge Fund Activity: Q1 2018 in Review
31 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2018, worth a combined $69.4M — down 16% from $82.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BLPH positions and 3 closed out — a net gain of 5 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $509K. The largest seller was Fidelity Investments, cutting an estimated $339K.
- 31 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2018, up from 26 in Q4 2017.
- Funds reported $69.4M of Bellerophon Therapeutics, Inc. stock for Q1 2018, down 16% quarter-over-quarter.
- 8 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2018 and 3 closed out, a net change of +5 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q1 2018 was Vanguard Group, an estimated $509K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q1 2018 was Fidelity Investments, an estimated $339K sold.
Based on aggregated 13F filings for Q1 2018.